Earnings summaries and quarterly performance for Zai Lab.
Executive leadership at Zai Lab.
Board of directors at Zai Lab.
Research analysts who have asked questions during Zai Lab earnings calls.
AR
Anupam Rama
JPMorgan Chase & Co.
6 questions for ZLAB
Also covers: APLS, BBIO, BOLD +18 more
JC
Jonathan Chang
Leerink Partners
6 questions for ZLAB
Also covers: ADAP, GMAB, IMCR +10 more
LW
Li Wang Watsek
Cantor Fitzgerald
5 questions for ZLAB
Also covers: AFMD, ALXO, ARVN +7 more
Michael Yee
Jefferies
5 questions for ZLAB
Also covers: ABBV, ALLO, AMGN +19 more
YN
Yigal Nochomovitz
Citigroup Inc.
4 questions for ZLAB
Also covers: ALDX, APLS, ARCT +22 more
HL
Haichong Lin
Goldman Sachs
2 questions for ZLAB
Linhai Zhao
Goldman Sachs
2 questions for ZLAB
LC
Louise Chen
Cantor Fitzgerald
2 questions for ZLAB
Also covers: AMGN, ARDX, CNTB +18 more
PH
Po Han Lin
Morgan Stanley
2 questions for ZLAB
SZ
Shuhui Zhao
Jefferies
2 questions for ZLAB
C
Caroline
Citi
1 question for ZLAB
Also covers: ARVN
JL
Jack Lin
Morgan Stanley
1 question for ZLAB
LH
Lin Hisao
Goldman Sachs
1 question for ZLAB
RL
Rebecca Liang
Sanford C. Bernstein & Co.
1 question for ZLAB
Also covers: ONC
Ziyi Chen
Goldman Sachs & Co.
1 question for ZLAB
Also covers: BGNE, LEGN, ONC
Recent press releases and 8-K filings for ZLAB.
Zai Lab Reports Q4 and Full Year 2025 Financial Results, Highlights Pipeline Progress
ZLAB
Earnings
Product Launch
New Projects/Investments
5 days ago
Zai Lab Reports Q4 and Full Year 2025 Financial Results, Highlights Pipeline Progress
ZLAB
Earnings
Product Launch
New Projects/Investments
- Zai Lab reported Q4 2025 revenue of $127.6 million, a 17% year-over-year increase, and full-year 2025 revenue of $460.2 million, up 15% year-over-year.
- For full-year 2025, loss from operations improved by 19% to $229.4 million, driven by a 6% decline in R&D expenses and a 7% decrease in SG&A expenses. The company ended Q4 2025 with a strong cash position of $790 million.
- The company is focused on achieving corporate profitability/cash flow breakeven and expects several meaningful pipeline catalysts in 2026, including clinical data for Zepzelca and first-in-human data for its IL-13/IL-31R bispecific program.
- Zai Lab anticipates the commercial launch of KarXT in Q2 2026 and expects potential U.S. approval for Zosi by 2028, with 75% patient enrollment for its pivotal trial by the end of 2026.
- Key regional pipeline readouts in H1 2026 include interim analysis for Povetacicept in IgAN and top-line data for Elegrobart in Thyroid Eye Disease, with TIVDAK approval in China expected in H1 2026.
5 days ago
Zai Lab Reports Q4 and Full Year 2025 Financial Results, Highlights Pipeline Progress
ZLAB
Earnings
Product Launch
Guidance Update
- Zai Lab reported total revenues of $127.6 million for Q4 2025, a 17% year-over-year increase, and $460.2 million for the full year 2025, a 15% year-over-year increase, primarily driven by XACDURO and NUZYRA.
- The company's adjusted operating loss improved by 25% year-over-year to ($148.8 million) for FY 2025, while maintaining a cash position of $790 million as of December 31, 2025.
- Zai Lab anticipates its first U.S. approval by 2028 and is advancing its lead asset, Zoci, with a Phase 3 study initiated for 2L/3L SCLC and an AA submission expected in 2027.
- Near-term regional launches are expected, including KarXT for Schizophrenia in Q2 2026 and anticipated approval of tivdak for Cervical Cancer in 1H 2026.
5 days ago
Zai Lab Reports Q4 and Full Year 2025 Financial Results, Highlights Pipeline Progress
ZLAB
Earnings
Product Launch
New Projects/Investments
- Zai Lab reported Q4 2025 revenue of $127.6 million, a 17% year-over-year increase, and full-year 2025 revenue of $460.2 million, up 15% year-over-year.
- The company's full-year 2025 loss from operations improved by 19% to $229.4 million, and it maintained a strong cash position of $790 million at quarter-end.
- Zai Lab's global oncology asset, Zoci, advanced rapidly, with a global registrational Phase 3 study initiated and anticipated potential accelerated approval submission in 2027 and first global approval in 2028.
- For 2026, Zai Lab expects several meaningful pipeline catalysts and plans commercial launches for KarXT in Q2 2026 and TIVDAK in China in H1 2026.
5 days ago
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results
ZLAB
Earnings
Revenue Acceleration/Inflection
Product Launch
- Zai Lab reported total revenues of $127.6 million for the fourth quarter of 2025 and $460.2 million for the full year 2025, representing 17% and 15% year-over-year growth, respectively. The net loss for Q4 2025 was $50.4 million and $175.5 million for FY 2025, a decrease from the prior year.
- The company maintained a strong liquidity position with $789.6 million in cash and cash equivalents, short-term investments, and current restricted cash as of December 31, 2025.
- XACDURO demonstrated significant growth, with revenues increasing 225% year-over-year to $10.7 million in Q4 2025 and 593% to $22.9 million for FY 2025. NUZYRA also grew 45% in Q4 2025 to $16.0 million and 41% for FY 2025 to $60.8 million.
- Strategic advancements include the approval of KarXT in China with a commercial launch planned for the first half of 2026, and zocilurtatug pelitecan (zoci) progressing towards three registration-enabling studies by the end of 2026, positioning it as Zai Lab’s first global oncology launch.
5 days ago
Zai Lab Discusses Oncology Pipeline and 2026 Milestones
ZLAB
Product Launch
New Projects/Investments
Guidance Update
- Zai Lab's lead product, Zoci (DLL3 ADC), is in Phase III for small cell lung cancer, having demonstrated a 68% response rate in Phase I/II studies and an 80% response rate in brain metastasis. An accelerated approval filing is anticipated in 2027, with a PDUFA timeline in 2028.
- The company plans to launch COBENFY and TIVDAK in 2026 and is filing for approval of Tumor Treating Fields (TTF) in pancreatic cancer, with expected approval in 2026.
- Zai Lab is advancing its pipeline with several assets, including the LRRC15 ADC in Phase I, and plans to file INDs for ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3) in 2026.
- Efficacy data for ZL-1503 for atopic dermatitis is expected in the second half of 2026.
Feb 19, 2026, 7:30 PM
Zai Lab Provides Update on Zoci Phase III Progress and 2026 Pipeline Milestones
ZLAB
Product Launch
New Projects/Investments
- Zai Lab's lead product, Zoci (DLL3 ADC), is in Phase III for small cell lung cancer, having demonstrated a 68% overall response rate in earlier studies. The company anticipates a potential accelerated approval filing in 2027 with a PDUFA timeline in 2028.
- The company plans to file for approval of Tumor Treating Fields (TTF) in pancreatic cancer this year, with expected approval in 2026. Zai Lab is already selling TTF for glioblastoma (GBM).
- Other key pipeline developments include the Phase I initiation of LRRC15 ADC (6201) and expected efficacy data for ZL-1503 in atopic dermatitis in the second half of 2026.
- Zai Lab is transitioning to a more global enterprise, leveraging its efficient engine in China to screen global products and plans to launch products in the United States.
Feb 19, 2026, 7:30 PM
Zai Lab Provides Update on Global Pipeline and Key Product Milestones
ZLAB
New Projects/Investments
Product Launch
Guidance Update
- Zai Lab's lead product, Zoci (DLL3 ADC), is in Phase III for small cell lung cancer, demonstrating a 68% response rate and over 6 months durability in Phase I/II studies. The company anticipates filing for accelerated approval in 2027, with a potential PDUFA timeline in 2028.
- The company is expanding its oncology pipeline, with LRRC15 ADC (6201) recently entering Phase I, and ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3) expected to enter the clinic in 2026.
- Zai Lab plans to launch COVEMVY and TIVDAK in 2026 and expects regulatory approval for tumor treating fields (TTF) in pancreatic cancer this year.
- The company is strategically transitioning from a local China business to a global enterprise, aiming to launch products in the United States and become a global company.
Feb 19, 2026, 7:30 PM
Zai Lab Highlights Strong Financial Position and Pipeline Progress at JPMorgan Healthcare Conference
ZLAB
Product Launch
New Projects/Investments
Guidance Update
- Zai Lab reported a strong cash position of $817 million as of September 2025 and a profitable China commercial business with sales around $460 million, providing a financial foundation for the company.
- In China, the company recently received approval for Cobenfy for schizophrenia, with a launch planned for the first half of 2026 and an NRDL listing target of 2027, while Vyvgart is expected to be a top-line growth driver in 2026 and beyond.
- Zai Lab's lead global asset, ZOSI (DLL3-focused ADC) for small cell lung cancer, has a Phase III trial underway (initiated Q4 2025) with potential for accelerated approval in the U.S. as early as 2028.
- Further global pipeline advancements include the IL-13/31 (1503) program for atopic dermatitis (Phase I data by end of 2027) and the planned initiation of a Phase I study for LRC-15 ADC in solid tumors in 2026.
- The company emphasizes leveraging its China expertise for efficient R&D and expects modest R&D growth in the near term, with tightly managed SG&A, leading to a clear path to profitability.
Jan 13, 2026, 11:00 PM
ZLAB Highlights Strong Financial Position and Global Pipeline at J.P. Morgan Healthcare Conference
ZLAB
New Projects/Investments
Product Launch
Guidance Update
- ZLAB reported a robust cash position of $817.2 million as of September 30, 2025, and is focused on near-term margin expansion and a path toward profitability.
- The company anticipates its first U.S. approval by 2028, with its lead asset, Zoci (DLL3 ADC), in a pivotal study demonstrating potential best-in-class efficacy and safety.
- ZLAB is expanding its global pipeline with over 9 indications in development by 2030 and expects a catalyst-rich year in 2026, including global phase 1 data for Zoci and potential China approval for TIVDAK.
Jan 13, 2026, 11:00 PM
Quarterly earnings call transcripts for Zai Lab.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more